[Immunomodulation in cancer. What do we do and where do we go?].
In the last few years we have witnessed a reorientation process in the diagnosis and treatment of cancer, and advances in cancer research point to the need for selective or specific immunomodulation therapies. In this article we remark on generalities of the immune response against tumors, highlighting both: mechanisms that underlie immune evasion by tumors and host defense mechanisms against malignancies. We also discuss current experience with the use of biological response modifiers in cancer and of immunomodulation therapies, in terms of accumulated effectiveness and adverse events of new biological response modifiers. We conclude that therapies with BRMs are hopeful and effective strategies to treat cancer, either alone or in combination with chemotherapy, surgery or radiations. Immunomodulation seem to be one of the most promising therapies for the control of malignant diseases.
Rodríguez Orozco
Alain R
AR
Retorno del Colegio Militar 145, Col. Chapultepec Sur, Morelia, Michocan, CP. arorozco@hotmail.com
Serriteño
Nicolas Medina
NM
D000917:Antibody Formation; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005544:Forecasting; D006801:Humans; D007111:Immunity, Cellular; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D019139:Tumor Escape / Q000276:immunology
D000970:Antineoplastic Agents; D007155:Immunologic Factors